Evidence map›Paper›PMID 42230935›Full record

ArticleScientific reports2026

Development of 1-(substituted benzofuran-2-yl)-3-(halogen-substituted phenyl)prop-2-en-1-ones as potent, reversible, and selective MAO-B inhibitors for Parkinson's Disease.

Ali Hasan, Jiseong Lee, Naresh Payyaula, Vishnu Vasanthi Radhakrishanan, Sachithra Thazhathuveedu Sudevan, Sunil Kumar, Della Grace Thomas Parambi, Kasim Sakran Abass, Arun Kumar, Naseer Maliyakkal and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ali HasanDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India.
Jiseong Lee *Department of Pharmacy, College of Pharmacy, SunchonNational University, Suncheon, 57922, Republic of Korea.
Naresh Payyaula *Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India.
Vishnu Vasanthi RadhakrishananDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India.
Sachithra Thazhathuveedu SudevanDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India.
Sunil KumarDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India.
Della Grace Thomas ParambiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Jouf University, Sakaka Al Jouf, 72341, Saudi Arabia.
Kasim Sakran AbassDepartment of Physiology, Biochemistry, and Pharmacology, College of Veterinary Medicine, University of Kirkuk, Kirkuk, 36001, Iraq.
Arun KumarSchool of Pharmacy, Sharda University, Knowledge Park III, Greater Noida, India.
Naseer MaliyakkalDepartment of Anesthesia and Operations, College of Applied Medical Sciences, King Khalid University, Khamis Mushait, Kingdom of Saudi Arabia.
Hoon KimDepartment of Pharmacy, College of Pharmacy, SunchonNational University, Suncheon, 57922, Republic of Korea. hoon@sunchon.ac.kr.
Bijo MathewDepartment of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi, 682 041, India. bijomathew@aims.amrita.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ten halogenated benzofuran derivatives (BF1-BF10) were synthesized and evaluated for their inhibitory activity against monoamine oxidase isoforms. All compounds showed stronger inhibition of MAO-B compared to MAO-A. Among them, BF2 exhibited the most potent MAO-B inhibition (IC₅₀ = 0.082 µM), followed by BF5 (IC₅₀ = 0.095 µM) and BF1 (IC₅₀ = 0.16 µM), with high selectivity indices, particularly BF2 (SI = 1038.05). Kinetic studies revealed that BF2 acts as a competitive inhibitor with a K

Indexed as

BenzofuransMonoamine OxidaseMonoamine Oxidase InhibitorsParkinson DiseaseAnimalsBenzylaminesBlood-Brain BarrierCatalytic DomainCell LineHumansKineticsMiceMolecular Docking SimulationMolecular Dynamics SimulationStructure-Activity RelationshipBenzofuransBenzylaminesMonoamine OxidaseMonoamine Oxidase InhibitorsBenzofuranChalconeKineticsMAO-BMolecular dockingReversibility

Identifiers

PMID42230935
PMCPMC13562588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.